Key Insights

Highlights

Success Rate

89% trial completion (above average)

Treatment Research

6 treatments under study, led by Apd209 Eye Drops

Research Leaders

7 sponsors active, led by NicOx

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

11.1%

1 terminated out of 9 trials

Success Rate

88.9%

+2.3% vs benchmark

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed with results

Key Signals

1 with results89% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Phase 2 (1)
Phase 3 (1)
Phase 4 (1)

Trial Status

Completed8
Terminated1

Trial Success Rate

88.9%

Benchmark: 86.6%

Based on 8 completed trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03861728Not ApplicableTerminatedPrimary

Viral Conjunctivitis Treatment Study

NCT03055065CompletedPrimary

ADenoVirus Initiative Study in Epidemiology in Italy

NCT02054273CompletedPrimary

ADenoVirus Initiative Study in Epidemiology in Germany

NCT02254330CompletedPrimary

ADenoVirus Initiative Study in Epidemiology in Spain

NCT01977443Phase 2CompletedPrimary

Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)

NCT02112773CompletedPrimary

ADenoVirus Initiative Study in Epidemiology in UK

NCT02054234CompletedPrimary

ADenoVirus Initiative Study in Epidemiology in France

NCT01481519Phase 3CompletedPrimary

A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis

NCT01179412Phase 4CompletedPrimary

Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine

Showing all 9 trials

Research Network

Common Treatments

  • Apd209 Eye Drops1
  • Artificial Tears1
  • Dexamethasone 01povidoneiodine 041
  • 001 Hypochlorous Acid1
  • Apd209 Placebo Eye Drops1

Active Sponsors

  • NicOx5
  • Mahidol University1
  • Adenovir Pharma AB1
  • NovaBay Pharmaceuticals, Inc.1
  • TFS Trial Form Support1

Top Investigators

Activity Timeline